WO2022178848A1 - Composition pour améliorer un tensioactif - Google Patents

Composition pour améliorer un tensioactif Download PDF

Info

Publication number
WO2022178848A1
WO2022178848A1 PCT/CN2021/078213 CN2021078213W WO2022178848A1 WO 2022178848 A1 WO2022178848 A1 WO 2022178848A1 CN 2021078213 W CN2021078213 W CN 2021078213W WO 2022178848 A1 WO2022178848 A1 WO 2022178848A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
weight
component
composition
group
Prior art date
Application number
PCT/CN2021/078213
Other languages
English (en)
Inventor
Yu Huang
Lingling Sun
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'oreal filed Critical L'oreal
Priority to CN202180094694.8A priority Critical patent/CN116940321A/zh
Priority to PCT/CN2021/078213 priority patent/WO2022178848A1/fr
Priority to FR2102884A priority patent/FR3120195B1/fr
Publication of WO2022178848A1 publication Critical patent/WO2022178848A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • the present invention relates to a composition for improving surfactant.
  • Skin is present widely on surface of human bodies. Many people have for a long time sought to fresh the body surface, so as to feel comfortable in daily life and work. It has always been an ultimate target of the cosmetic filed to deliver products with skin benefits such as hydration, moisturizing, anti-aging, whitening, cleansing, slippery feeling and so on.
  • SC stratum corneum
  • a skin care product is often provided as a leave-on form, which means successive and long-term contact of the product with skin.
  • one or more surfactants are added into the skin care products, especially for the leave-on products. It is however known that various surfactants may cause irritation to skin.
  • the inventors have surprisingly discovered that by using specifically combination of at least one specific polymer, especially at least one hydrophobic modified ammonium acryloyldimethyltaurate acid or salt, with a conventionally irritative surfactant, the irritation result will be quite inhibited.
  • composition for improving surfactant comprising:
  • At least one conventionally irritative surfactant having an EpiSkin cell viability of equal to or less than 90%, preferably equal to or less than 85%;
  • composition according to the present invention is particularly useful for improving surfactant, in particular in a skin care product, e.g., a product for the stratum corneum.
  • a skin care product e.g., a product for the stratum corneum.
  • the composition of the present invention can be particularly a leave-on product in various form, in particular solution, such as lotion, spray and the like to be applied to directly to skin.
  • the present invention is directed to an aqueous composition for improving surfactant, comprising the components of:
  • the present invention thus provides use of combination of at least one hydrophobic AMPS copolymer of component A) and at least one conventionally irritative surfactant of component B) for enhancing the performance of a skin care product while avoiding or reducing the irritation suffered by skin, especially that caused by the conventionally irritative surfactant.
  • composition according to the present invention may comprise a hydrophobic AMPS copolymer.
  • the useful hydrophobic AMPS copolymers can be crosslinked or non-crosslinked copolymers comprising at least the acrylamido-2-methylpropanesulfonic acid monomer, optionally in a form partially or totally neutralized with ammonia or with a mineral base other than ammonia, such as sodium hydroxide or potassium hydroxide.
  • Representative AMPS polymers are those commercially available from THE LUBRIZOL CORPORATION under the name
  • the hydrophobic AMPS copolymers are preferably totally neutralized or virtually totally neutralized, i.e. at least 90%neutralized.
  • the hydrophobic AMPS copolymers are preferably crosslinked.
  • the hydrophobic AMPS copolymers are preferably in a form partially or totally neutralized with ammonia.
  • the hydrophobic AMPS copolymers are preferably copolymers of hydrophobically modified ammonium acryloyldimethyltaurate acid or salt.
  • the crosslinking agents may be chosen from the polyolefinically unsaturated compounds commonly used for the crosslinking of polymers obtained by free-radical polymerization.
  • crosslinking agents examples include divinylbenzene; ethers, such as diallyl ether, dipropylene glycol diallyl ether, polyglycol diallyl ethers, triethylene glycol divinyl ether, trimethylolpropane diallyl ether, allylic ethers of alcohols of the sugar series, or other allylic or vinyl ethers of polyfunctional alcohols, hydroquinone diallyl ether; esters, such as, triallyl cyanurate, diallyl maleate, also allylic esters of phosphoric and/or vinylphosphonic acid derivatives, and especially (meth) acrylate of fatty acids, such as ethylene glycol or tetraethylene glycol di (meth) acrylate, trimethylolpropane triacrylate, allyl (meth) acrylate; amides, such as methylenebisacrylamide, methylenebismethacrylamide, triallylamine, tetraallylethylenediamine, and or
  • the degree of crosslinking generally ranges from 0.01 mol%to 10 mol%and more particularly from 0.2 mol%to 2 mol%relative to the polymer.
  • the AMPS polymer in accordance with the invention is preferably water-soluble or water-dispersible. In this case they are preferably:
  • water-soluble or water-dispersible means polymers which, when introduced into an aqueous phase at 25°C, to a mass concentration equal to 1%, make it possible to obtain a macroscopically homogeneous and transparent solution, i.e. a solution that has a maximum light transmittance value, at a wavelength equal to 500 nm, through a sample 1 cm thick, of at least 60%and preferably of at least 70%.
  • the water-soluble or water-dispersible AMPS copolymers according to the invention contain water-soluble ethylenically unsaturated monomers, hydrophobic monomers or mixtures thereof.
  • the water-soluble comonomers may be ionic or nonionic.
  • ionic water-soluble comonomers examples that may be mentioned include the following compounds and the salts thereof:
  • - R 1 is chosen from H, -CH 3 , -C 2 H 5 and-C 3 H 7
  • R 2 is a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbon atoms, substituted with at least one sulfonic (-SO 3 -) and/or sulfate (-SO 4 -) and/or phosphate (-PO 4 H 2 -) group.
  • nonionic water-soluble comonomers examples that may be mentioned include:
  • N-vinyllactams comprising a cyclic alkyl group containing 4 to 9 carbon atoms, such as n-vinylpyrrolidone, N-butyrolactam and N-vinylcaprolactam,
  • - R 15 is chosen from H, -CH 3 , -C 2 H 5 and-C 3 H 7
  • R 16 is a linear or branched, saturated or unsaturated hydrocarbon-based radical containing from 1 to 6 carbons, optionally substituted with a halogen atom (iodine, bromine, chlorine or fluorine) ; a hydroxyl group (-OH) ; ether.
  • the AMPS polymer, preferably water-soluble or water-dispersible, of the invention preferably have a molar mass ranging from 50 000 g/mol to 10 000 000 g/mol, preferably from 80 000 g/mol to 8 000 000 g/mol or from 100 000 g/mol to 7 000 000 g/mol.
  • crosslinked AMPS copolymer is HMS, ammonium acryloyldimethyltaurate/steareth-25 methacrylate crosspolymer; non-crosslinked AMPS copolymer is SNC, ammonium acryloyldimethyltaurate/steareth-8 methacrylate copolymer.
  • water-soluble or water-dispersible AMPS copolymers examples include:
  • CTFA name Polyacrylamide/C 13 -C 14 Isoparaffin/Laureth-7) or the copolymer used in the commercial product sold under the trade name 600 (CTFA name: Acrylamide/Sodium Acryloyldimethyltaurate/Isohexadecane/Polysorbate-80) by the company SEPPIC;
  • AMPS/sodium acrylate copolymer such as the copolymer used in the commercial product sold under the name EG by the company SEPPIC (CTFA name: Acrylamide/Sodium Acryloyldimethyltaurate/Isohexadecane/Polysorbate-80) ;
  • AMPS/hydroxyethyl acrylate copolymer such as the copolymer used in the commercial product sold under the name NS by the company SEPPIC (CTFA name: Hydroxyethyl acrylate/Sodium Acryloyldimethyltaurate copolymer (and) Squalane (and) Polysorbate-60) ;
  • the preferred polymers are more particularly ammonium polyacryloyldimethyl taurate; and AMPS/hydroxyethyl acrylate copolymers, such as the copolymer used in the commercial product sold under the name Simulgel NS, or ammonium acryloyldimethyltaurate/steareth-25 methacrylate crosspolymer.
  • the component A) of hydrophobic AMPS copolymer in accordance with the invention are generally present in amounts ranging from 0.01%to 10%by weight, preferably 0.1%to 5%by weight, or particularly from 0.3%to 3%by weight, or preferably from 0.5%to 2%by weight relative to the total weight of the composition.
  • Component B) conventionally irritative surfactant
  • Surfactants are generally added into the skin care products. Meanwhile, various surfactants may cause irritation to skin. Amongst others, it is known that cationic surfactant is readily to be irritative.
  • the conventionally irritative surfactant particularly useful for component B) may be those having an EpiSkin cell viability of equal to or less than 90%, preferably equal to or less than 85%, or even equal to or less than 80%.
  • the EpiSkin cell viability can be determined through the steps of: applying effective amount the compositions on reconstructed skin model, i.e., the EpiSkin, standing, and then making statistic of the viable cell amount, in which the "EpiSkin" is available from L'Oreal under the name of EpiSkin TM .
  • component A) when being used in combination with the conventionally irritative surfactant of component B) in an aqueous composition, can well swell in the solvent or medium, e.g., water, with any pH environment. Accordingly, the hydrophobic chain of component A) will attend to generate micellar with the surfactant of component B) , which will decrease the free monomer of the surfactant, and slow release the surfactant to penetrate into skin, in this way, the skin irritation can be effectively reduced.
  • solvent or medium e.g., water
  • the component B) may comprise: component B-1) , cationic surfactant; component B-2) , nonionic surfactant; and/or component B-3) , amphoteric surfactant, preferably having an EpiSkin cell viability of equal to or less than 90%, preferably equal to or less than 85%, or even equal to or less than 80%.
  • Component B-1 Cationic surfactant
  • the composition of the present invention may comprise at least one cationic surfactant useful as component B-1) .
  • Mention may be made, for example, of optionally polyoxyalkylenated primary, secondary or tertiary fatty amine salts, quaternary ammonium salts, and mixtures thereof.
  • quaternary ammonium salts examples include:
  • the groups R 8 to R 11 which may be identical or different, represent a linear or branched aliphatic group comprising from 1 to 30 carbon atoms or an aromatic group such as aryl or alkylaryl, at least one of the groups R 8 to R 11 comprising from 8 to 30 carbon atoms and preferably from 12 to 24 carbon atoms.
  • the aliphatic groups may comprise heteroatoms such as, in particular, oxygen, nitrogen, sulfur and halogens.
  • X - for formula (V) is an anionic counterion chosen from halides, phosphates, acetates, lactates, (C 1 -C 4 ) alkyl sulfates, and (C 1 -C 4 ) alkyl-or (C 1 -C 4 ) alkylarylsulfonates, preferably halides, e.g., fluoride, chloride, bromide or the like.
  • the aliphatic groups are chosen, for example, from C 1 -C 30 alkyl, C 1 -C 30 alkoxy, polyoxy (C 2 -C 6 ) alkylene, C 1 -C 30 alkylamide, (C 12 -C 22 ) alkylamido (C 2 -C 6 ) alkyl, (C 12 -C 22 ) alkylacetate, C 1 -C 30 hydroxyalkyl.
  • tetraalkylammonium halides such as tetraalkylammonium chlorides, for instance tetraalkylammonium or alkyltrimethylammonium halides such as dialkyldimethylammonium or alkyltrimethylammonium chlorides in which the alkyl group contains from approximately 12 to 22 carbon atoms, in particular halides such as behenyltrimethylammonium chloride, distearyldimethylammonium chloride, cetyltrimethylammonium chloride, benzyldimethylstearylammonium chloride, or else, secondly, alkoxy sulfates, especially distearoylethylhydroxyethylmethylammonium methosulfate, dipalmitoylethylhydroxyethylammonium methosulfate or distearoylethylhydroxyethylammonium
  • R 12 represents an alkenyl or alkyl group comprising from 8 to 30 carbon atoms, for example fatty acid derivatives of tallow;
  • R 13 represents a hydrogen atom, a C 1 -C 4 alkyl group or an alkenyl or alkyl group comprising from 8 to 30 carbon atoms;
  • R 14 represents a C 1 -C 4 alkyl group
  • R 15 represents a hydrogen atom or a C 1 -C 4 alkyl group
  • X - for formula (VI) represents an anionic counterion chosen in particular from halides, phosphates, acetates, lactates, (C 1 -C 4 ) alkyl sulfates, (C 1 -C 4 ) alkyl- or (C 1 -C 4 ) alkylarylsulfonates.
  • R 12 and R 13 preferably denote a mixture of alkyl or alkenyl groups containing from 12 to 21 carbon atoms, derived for example from tallow fatty acids, R 14 preferably denotes a methyl group, and R 15 preferably denotes a hydrogen atom.
  • a product is sold, for example, under the name W 75 by the company Rewo;
  • R 16 denotes an alkyl group comprising from about 16 to 30 carbon atoms, which is optionally hydroxylated and/or interrupted with one or more oxygen atoms;
  • R 17 is chosen from hydrogen, an alkyl group comprising from 1 to 4 carbon atoms or a group- (CH 2 ) 3 -N + (R 16a ) (R 17a ) (R 18a ) ; R 16a , R 17a , R 18a , R 18 , R 19 , R 20 and R 21 , which may be identical or different, are chosen from hydrogen and an alkyl group comprising from 1 to 4 carbon atoms, and
  • X - for formula (VII) represents an anionic counterion chosen in particular from halides, acetates, phosphates, nitrates, (C 1 -C 4 ) alkyl sulfates, (C 1 -C 4 ) alkyl- or (C 1 -C 4 ) alkylarylsulfonates, in particular methyl sulfate and ethyl sulfate.
  • Such compounds are, for example, Finquat CT-P, available from the company Finetex (Quaternium 89) , and Finquat CT, available from the company Finetex (Quaternium 75) ;
  • ⁇ R 22 is chosen from C 1 -C 6 alkyl and C 1 -C 6 hydroxyalkyl or dihydroxyalkyl groups;
  • ⁇ R 23 is chosen from:
  • ⁇ R 25 is chosen from:
  • ⁇ R 24 , R 26 and R 28 which may be identical or different, are chosen from linear or branched, saturated or unsaturated C 7 -C 21 hydrocarbon-based groups;
  • ⁇ r, s and t which may be identical or different, are integers ranging from 2 to 6;
  • ⁇ y is an integer ranging from 1 to 10;
  • ⁇ x and z which may be identical or different, are integers ranging from 0 to 10;
  • ⁇ X - for formula (VIII) represents an organic or inorganic anionic counterion
  • the alkyl groups R 22 may be linear or branched, and more particularly linear.
  • R 22 denotes a methyl, ethyl, hydroxyethyl or dihydroxypropyl group, and more particularly a methyl or ethyl group.
  • the sum x+y+z is from 1 to 10.
  • R 23 is a hydrocarbon-based group R 27 , it may be long and may contain from 12 to 22 carbon atoms, or may be short and may contain from 1 to 3 carbon atoms.
  • R 25 is a hydrocarbon-based group R 29 , it preferably contains 1 to 3 carbon atoms.
  • R 24 , R 26 and R 28 which may be identical or different, are chosen from linear or branched, saturated or unsaturated C 11 -C 21 hydrocarbon-based groups, and more particularly from linear or branched, saturated or unsaturated C 11 -C 21 alkyl and alkenyl groups.
  • x and z which may be identical or different, are equal to 0 or 1.
  • y is equal to 1.
  • r, s and t which may be identical or different, are equal to 2 or 3, and even more particularly are equal to 2.
  • the anionic counterion X - for formula (VIII) is preferably a halide, preferably such as chloride, bromide or iodide, a (C 1 -C 4 ) alkyl sulfate or a (C 1 -C 4 ) alkyl- or (C 1 -C 4 ) alkylaryl-sulfonate.
  • a halide preferably such as chloride, bromide or iodide
  • methanesulfonate, phosphate, nitrate, tosylate an anion derived from an organic acid, such as acetate or lactate, or any other anion compatible with the ammonium containing an ester function.
  • the anionic counterion X - for formula (VIII) is even more particularly chloride, methyl sulfate or ethyl sulfate.
  • R 22 denotes a methyl or ethyl group
  • - R 25 is chosen from:
  • R 24 , R 26 and R 28 which may be identical or different, are chosen from linear or branched, saturated or unsaturated C 13 -C 17 hydrocarbon-based groups, and more particularly from linear or branched, saturated or unsaturated C 13 -C 17 alkyl and alkenyl groups.
  • hydrocarbon-based radicals are linear.
  • quaternary ammonium salts containing one or more ester functions of formula (VIII) examples that may be mentioned include salts, especially the chloride or methyl sulfate, of diacyloxyethyldimethylammonium, diacyloxyethylhydroxy-ethylmethylammonium, monoacyloxyethyldihydroxyethylmethylammonium, triacyloxy-ethylmethylammonium or monoacyloxyethylhydroxyethyldimethylammonium, and mixtures thereof.
  • the acyl groups preferably contain 14 to 18 carbon atoms and are obtained more particularly from a plant oil such as palm oil or sunflower oil. When the compound contains several acyl groups, these groups may be identical or different.
  • This esterification is followed by a quaternization by means of an alkylating agent such as an alkyl halide, preferably methyl or ethyl halide, a dialkyl sulfate, preferably methyl or ethyl sulfate, methyl methanesulfonate, methyl para-toluenesulfonate, glycol chlorohydrin or glycerol chlorohydrin.
  • an alkylating agent such as an alkyl halide, preferably methyl or ethyl halide, a dialkyl sulfate, preferably methyl or ethyl sulfate, methyl methanesulfonate, methyl para-toluenesulfonate, glycol chlorohydrin or glycerol chlorohydrin.
  • Such compounds are sold, for example, under the names by the company Henkel, by the company Stepan, by the company Ceca or WE 18 by the company Rewo-Witco.
  • composition according to the invention may contain, for example, a mixture of quaternary ammonium salts of mono-, di-and triesters with a weight majority of diester salts.
  • ammonium salts containing at least one ester function that are described in patents US-A-4 874 554 and US-A-4 137 180.
  • Use may be made of behenoylhydroxypropyltrimethylammonium chloride sold by KAO under the name Quatarmin BTC 131.
  • the ammonium salts containing at least one ester function contain two ester functions.
  • Some amines may provide cations when being interacted with other reagents, e.g., certain acids. In such cases, the specific amines may be classified into the useful cationic surfactant.
  • Preferred examples of the useful cationic surfactant comprise non-silicone cationic surfactants, including cetyl triammonium, behenyl triammonium, dipalmitoylethyl hydroxyethyl methyl ammonium, distearoylethyl hydroxyethyl methyl ammonium, methyl (C9-C19) alkyl, (C10-C20) alkyl amidoethylimidazolium, and stearamidopropyldimethylamine, a salt of stearamidopropyl dimethylammonium, and mixtures thereof.
  • non-silicone cationic surfactants including cetyl triammonium, behenyl triammonium, dipalmitoylethyl hydroxyethyl methyl ammonium, distearoylethyl hydroxyethyl methyl ammonium, methyl (C9-C19) alkyl, (C10-C20) alkyl amidoe
  • the cationic surfactant is the chloride and bromide salts of tetraalkylammonium, alkylamidoalkyltrialkylammonium, trialkylbenzylammonium, trialkylhydroxyalkylammonium or alkylpyridinium.
  • cationic surfactants that may be present in the composition according to the invention, it is more particularly preferred to choose stearamidopropyldimethyl (myristyl acetate) ammonium chloride, cetyltrimethylammonium, behenyltrimethylammonium and dipalmitoylethylhydroxyethylmethylammonium salts, and mixtures thereof, and more particularly stearamidopropyldimethyl (myristyl acetate) ammonium chloride, behenyltrimethylammonium chloride, cetyltrimethylammonium chloride, and dipalmitoylethylhydroxyethylammonium methosulfate, and mixtures thereof.
  • the component B-1) may preferably have an EpiSkin cell viability of equal to or less than 90%, preferably equal to or less than 85%, or even equal to or less than 80%.
  • the component B-1) may be present in the composition according to the present invention in an amount ranging from 0.001%to 10%by weight, preferably from 0.005%to 5%by weight, or from 0.01%to 3%by weight, relative to the weight of the composition.
  • Component B-2 nonionic surfactant
  • composition according to the present invention may preferably comprise at least one nonionic surfactant, which may be fatty acid ester or ether of polyglycerol, or other conventional irritative surfactant, for use as component B-2) .
  • nonionic surfactant which may be fatty acid ester or ether of polyglycerol, or other conventional irritative surfactant, for use as component B-2) .
  • mono-or poly-glycerolated surfactants may be used, which preferably comprise on average from 1 to 30 glycerol groups, more particularly from 1 to 10 glycerol groups and in particular from 1.5 to 5.
  • the monoglycerolated or polyglycerolated surfactants are preferably chosen from the compounds of the following formulae:
  • ⁇ R represents a saturated or unsaturated, linear or branched hydrocarbon-based radical comprising from 8 to 40 carbon atoms and preferably from 10 to 30 carbon atoms; m is an integer between 1 and 30, preferably between 1 and 10 and more particularly from 1.5 to 6; R” may optionally comprise heteroatoms, for instance oxygen and nitrogen. In particular, R” may optionally comprise one or more hydroxyl and/or ether and/or amide groups. R” preferably denotes mono-or polyhydroxylated C 10 -C 20 alkyl, and/or alkenyl radicals.
  • Use may be made, for example, of the polyglycerolated (3.5 mol) hydroxylauryl ether sold under the name NF from Chimex.
  • the (poly) ethoxylated fatty alcohols that are suitable for performing the invention are chosen more particularly from alcohols containing from 8 to 30 carbon atoms, and preferably from 12 to 22 carbon atoms.
  • the (poly) ethoxylated fatty alcohols more particularly contain one or more linear or branched, saturated or unsaturated hydrocarbon-based groups, comprising 8 to 30 carbon atoms, which are optionally substituted, in particular with one or more (in particular 1 to 4) hydroxyl groups. If they are unsaturated, these compounds may comprise one to three conjugated or non-conjugated carbon-carbon double bonds.
  • the (poly) ethoxylated fatty alcohol (s) preferably have the following formula (XII) :
  • R 3 representing a linear or branched C 8 -C 40 alkyl or alkenyl group and preferably C 8 -C 30 alkyl or alkenyl group, optionally substituted with one or more hydroxyl groups, and
  • - c is an integer between 1 and 200 inclusive, preferably between 2 and 50 and more particularly between 8 and 30, such as 20.
  • the composition may comprise at least one fatty acid ester of polyglycerol for use as a nonionic surfactant.
  • the fatty acid ester of polyglycerol is chosen from esters resulting from the reaction of polyglycerol comprising from 2 to 12 glycerol units, preferably from 3 to 10 glycerol units, and of at least one fatty acid containing from 6 to 24 carbon atoms, preferably from 8 to 20 carbon atoms, or from 8 to 18 carbon atoms.
  • the fatty acids containing from 8 to 24 carbon atoms may be linear or branched, and saturated or unsaturated.
  • the fatty acid esters of polyglycerol can be chosen from monoesters, diesters, triesters and tetraesters, polyesters and mixtures thereof. Use is preferably made of esters with a low degree of esterification, for instance fatty acid monoesters, diesters or triesters of polyglycerol, or a mixture.
  • the fatty acid ester of polyglycerol can be in the form of a mixture of esters with a low degree of esterification, for instance a mixture of monoester and diester or a mixture of monoester, diester and triester.
  • polyglyceryl-2 distearate in particular as sold by NIHON EMULSION under the name Emalex PGSA
  • polyglyceryl-10 decastearate in particular as sold by TAIYO KAGAKU under the name Sunsoft Q-1810S
  • polyglyceryl-5 hexastearate in particular as sold by TAIYO KAGAKU under the name Sunsoft A-186E
  • polyglyceryl-2 laurate in particular as sold by TAIYO KAGAKU under the name Sunsoft Q-12D
  • polyglyceryl-5 laurate in particular as sold by TAIYO KAGAKU under the name Sunsoft A-121E-C
  • polyglyceryl-10 pentaoleate in particular as sold by TAIYO KAGAKU under the name Sunsoft Q-175S
  • polyglyceryl-10 pentastearate in particular as sold by TAIYO KAGAKU under the name Sunsoft Q-185S
  • the composition according to the present invention may comprise at least one additional nonionic surfactant other than fatty acid ester or ether of polyglycerol, also for use as component B-2) .
  • Examples of the useful additional nonionic surfactants may comprise esters of polyols and of fatty acids with a saturated or unsaturated chain containing, for example, from 8 to 24 carbon atoms and better still from 12 to 22 carbon atoms, and the oxyalkylenated derivatives thereof, i.e.
  • derivatives containing oxyethylenated and/or oxypropylenated units e.g., oxyalkylenated derivatives thereof; the polyethylene glycol esters of C 8 -C 24 fatty acids, and the oxyalkylenated derivatives thereof; the sorbitol esters of C 8 -C 24 fatty acids, and the oxyalkylenated derivatives thereof; the sugar (sucrose, glucose or alkylglucose) esters of C 8 -C 24 fatty acids (fatty acid esters of glucose or of alkylglucose) , and the oxyalkylenated derivatives thereof; fatty alcohol ethers; the sugar ethers of C 8 -C 24 fatty alcohols, and mixtures thereof.
  • oxyalkylenated derivatives thereof the polyethylene glycol esters of C 8 -C 24 fatty acids, and the oxyalkylenated derivatives thereof; the sorbitol esters of C 8 -C 24 fatty
  • Fatty acid esters of glucose or of alkylglucose that may be mentioned in particular include glucose palmitate, alkylglucose sesquistearates, for instance methylglucose sesquistearate, alkylglucose palmitates, for instance methylglucose palmitate or ethylglucose palmitate, fatty esters of methylglucoside and more especially the diester of methylglucoside and of oleic acid (CTFA name: methyl glucose dioleate) ; the mixed ester of methylglucoside and of the oleic acid/hydroxystearic acid mixture (CTFA name: methyl glucose dioleate/hydroxysterate) ; the ester of methylglucoside and of isostearic acid (CTFA name: methyl glucose isostearate) ; the ester of methylglucoside and of lauric acid (CTFA name: methyl glucose laurate) ; the mixture of the monoester and diester of methylglucoside
  • oxyethylenated ethers of a fatty acid and of glucose or of alkylglucose examples include the oxyethylenated ethers of a fatty acid and of methylglucose, and in particular the polyethylene glycol ether of the diester of methyl glucose and of stearic acid containing about 20 mol of ethylene oxide (CTFA name: PEG-20 methyl glucose distearate) , such as the product sold under the name E-20 distearate by the company Amerchol; the polyethylene glycol ether of the mixture of monoester and diester of methylglucose and of stearic acid containing about 20 mol of ethylene oxide (CTFA name: PEG-20 methyl glucose sesquistearate) and in particular the product sold under the name SSE-20 by the company Amerchol, and the product sold under the name PSE-20 by the company Goldschmidt, and mixtures thereof.
  • CTFA name polyethylene glycol ether of the diester of methyl glucose and of
  • sucrose esters examples include sucrose palmitostearate, sucrose stearate and sucrose monolaurate.
  • fatty alcohol ethers examples include polyethylene glycol ethers of fatty alcohols containing from 8 to 30 carbon atoms and especially from 10 to 22 carbon atoms, such as polyethylene glycol ethers of cetyl alcohol, of stearyl alcohol or of cetearyl alcohol (mixture of cetyl alcohol and stearyl alcohol) .
  • ethers comprising from 1 to 200 and preferably from 2 to 100 oxyethylene groups, such as those of CTFA name Ceteareth-20 and Ceteareth-30, and mixtures thereof.
  • sugar ethers that may especially be mentioned are alkylpolyglucosides, for example decylglucoside, for instance the product sold under the name 10 by the company Kao Chemicals, the product sold under the name 2000 by the company Henkel, and the product sold under the name NS 10 by the company SEPPIC; caprylyl/capryl glucoside, for instance the product sold under the name CG 110 by the company SEPPIC or under the name GD 70 by the company BASF; laurylglucoside, for instance the products sold under the names 1200 N and 1200 by the company Henkel; cocoglucoside, for instance the product sold under the name Plantacare 818/UP by the company Henkel; cetostearyl glucoside optionally as a mixture with cetostearyl alcohol, sold, for example, under the name 68 by the company SEPPIC, under the name CG90 by the company Goldschmidt and under the name KE3302 by the company Henkel; arachidyl glucoside, for
  • PEG modified ester can also be used, such as PEG-7 Olivate, PEG-7 Glyceryl Cocoate, PEG-30 Glyceryl Cocoate, PEG-80 Glyceryl Cocoate.
  • Polysorbate series such as Polysorbate 20, 21, 60, 61 and 80, or glyceride compounds, such as caprylic glyceride (also called as monocaprylin) , capric glyceride (also called as monocaprin) , and lauric glyceride (also called as monolaurin) , e.g., PEG-6 caprylic/capric glyceride, may be additionally mentioned as examples of useful additional nonionic surfactants.
  • glyceride compounds such as caprylic glyceride (also called as monocaprylin) , capric glyceride (also called as monocaprin) , and lauric glyceride (also called as monolaurin) , e.g., PEG-6 caprylic/capric glyceride, may be additionally mentioned as examples of useful additional nonionic surfactants.
  • the at least one additional nonionic surfactant can itself serve as a solubilizer, so as to facilitate the dissolution or dispersion of the components in the aqueous composition.
  • the component B-2) may preferably have an EpiSkin cell viability of equal to or less than 90%, preferably equal to or less than 85%, or even equal to or less than 80%.
  • the component B-2) may be present in the composition according to the present invention in an amount ranging from 0.1%to 20%, such as from 0.5%to 10%, or from 1% to 5%, relative to the total weight of the composition.
  • Component B-3 amphoteric surfactant
  • the composition according to the present invention comprises at least one amphoteric surfactant as component B-3) , which may also be called as zwitterionic surfactant.
  • amphoteric or zwitterionic surfactant (s) that may be used in the present invention may be quaternized secondary or tertiary aliphatic amine derivatives containing at least one anionic group, for instance a carboxylate, sulfonate, sulfate, phosphate or phosphonate group, and in which the aliphatic group or at least one of the aliphatic groups is a linear or branched chain comprising from 8 to 22 carbon atoms.
  • ⁇ R 4 represents a C 10 -C 30 alkyl or alkenyl group derived from an acid R 4 -C (O) -OH preferably present in hydrolysed coconut oil, or a heptyl, nonyl or undecyl group;
  • ⁇ R 5 represents a ⁇ -hydroxyethyl group
  • ⁇ R 6 represents a carboxymethyl group
  • ⁇ A represents-CH 2 CH 2 OX'
  • ⁇ X' represents the group-CH 2 -C (O) -OH, -CH 2 -C (O) -OZ’, -CH 2 CH 2 -C (O) -OH, -CH 2 -CH 2 -C (O) -OZ’, or a hydrogen atom;
  • ⁇ Y' represents –C (O) -OH, –C (O) -OZ’ or the group -CH 2 -CH (OH) -SO 3 H or -CH 2 -CH (OH) -SO 3 Z’;
  • ⁇ Z’ represents an ion derived from an alkali or alkaline-earth metal, such as sodium, potassium or magnesium; an ammonium ion; or an ion derived from an organic amine and in particular from an aminoalcohol, such as mono-, di-and triethanolamine, mono-, di-or triisopropanolamine, 2-amino-2-methyl-1-propanol, 2-amino-2-methyl-1, 3-propanediol and tris (hydroxymethyl) aminomethane.
  • an alkali or alkaline-earth metal such as sodium, potassium or magnesium
  • an ammonium ion or an ion derived from an organic amine and in particular from an aminoalcohol, such as mono-, di-and triethanolamine, mono-, di-or triisopropanolamine, 2-amino-2-methyl-1-propanol, 2-amino-2-methyl-1, 3-propanediol and tris (hydroxymethyl) aminomethane
  • ⁇ R 7 represents a C 10 -C 30 alkyl or alkenyl group of an acid R 7 C (O) -OH preferably present in coconut oil or in hydrolysed linseed oil, an alkyl group, especially of C 17 and its iso form, or an unsaturated C 17 group.
  • N-cocoylamidocarboxymethyl glycinate of an alkali metal such as sodium, or cocoamphodiacetate sold for example by the company Rhodia under the trade name C2M concentrate.
  • betaine surfactant e.g., (C 8 -C 20 ) alkylbetaines, sulfobetaines, (C 8 -C 20 alkyl) amido (C 2 -C 8 alkyl) betaines and (C 8 –C 20 alkyl) amido (C 2 -C 8 alkyl) sulfobetaines.
  • a betaine surfactant e.g., (C 8 -C 20 ) alkylbetaines, sulfobetaines, (C 8 -C 20 alkyl) amido (C 2 -C 8 alkyl) betaines and (C 8 –C 20 alkyl) amido (C 2 -C 8 alkyl) sulfobetaines.
  • amphoteric surfactants use is preferably made of cocoylamidopropylbetaine, cocoylbetaine and the N-cocoylamidocarboxymethyl glycinate of an alkali metal such as sodium.
  • the amphoteric surfactant mentioned above is cocoylamidopropylbetaine or cocoylbetaine.
  • the component B-3) may preferably have an EpiSkin cell viability of equal to or less than 90%, preferably equal to or less than 85%, or even equal to or less than 80%.
  • the composition according to the present invention preferably does not comprise an anionic surfactant.
  • the composition according to the present invention is free of anionic surfactant.
  • composition according to the invention can advantageously comprise at least one medium/solvent, for use as component C) , including water and/or organic medium/solvent.
  • the composition according to the invention may advantageously comprise water in various amounts.
  • a relatively high amount of water may be used.
  • water is used in a content of greater than or equal to 40%by weight relative to the total weight of composition.
  • the water content in the low viscosity composition according to the invention preferably ranges from 40%to 99.9%by weight, from 50%to 99%by weight, or from 60%to 90%by weight, relative to the total weight of the composition.
  • composition according to the invention may also comprise one or more organic medium/solvents, preferably water-soluble organic medium/solvents (solubility of greater than or equal to 5%in water at 25°C and at atmospheric pressure) .
  • organic medium/solvents preferably water-soluble organic medium/solvents (solubility of greater than or equal to 5%in water at 25°C and at atmospheric pressure) .
  • organic medium/solvents examples include linear or branched, and preferably saturated, monoalcohols or diols, comprising 2 to 10 carbon atoms, such as ethanol, (iso) propanol, butanol, hexylene glycol (2-methyl-2, 4-pentanediol) , neopentyl glycol and 3-methyl-1, 5-pentanediol, butylene glycol, dipropylene glycol and propylene glycol; aromatic alcohols such as phenylethyl alcohol; polyols containing more than two hydroxyl functions, in particular C3-C6 polyols, such as glycerol; polyol ethers, for instance ethylene glycol monomethyl, monoethyl and monobutyl ether, propylene glycol or ethers thereof, for instance propylene glycol monomethyl ether; and also diethylene glycol alkyl ethers, especially C 1 -C 4 alkyl
  • the organic medium/solvents when they are present in an amount ranging from 0.1%to 40%by weight, preferably from 1%to 30%by weight, or from 5%to 20%by weight, relative to the total weight of the composition according to the invention.
  • composition according to the present invention may optionally comprise a preservative.
  • the preservative useful according to the present invention can be any one conventionally used for cosmetics, in particular for ampoule products.
  • preservatives can be used according to the present invention comprise methylchloroisothiazolinone, imidazolidinyl urea, derivatives of hydantoin, such as DMDMH, parahydroxybenzoate ester, phenoxyethanol, benzyl alcohol, chlorphenesin, benzoic acid and a derivative thereof, e.g., a salt thereof, such as sodium benzoate, potassium sorbate, hydroxyacetophenone, amino-acid based preservative, sorbitan octanate, glycerol caprylate and the like, or salicylic acid.
  • a salt thereof such as sodium benzoate, potassium sorbate, hydroxyacetophenone, amino-acid based preservative, sorbitan octanate, glycerol caprylate and the like, or salicylic acid.
  • the preservative can be present according to the invention in an amount ranging from 0.01 to 5%, preferably from 0.01%to 3%, or from 0.01%to 1%, relative to the total weight of the composition of the present invention.
  • the composition may comprise a chelating agent.
  • chelating agents are defined and described in particular in the article "Chelating agents” Kirk Othmer Encyclopedia of Chemical Technology, Vol. 5 pp. 708-739, published in 2003.
  • a chelating agent are made to polyphosphates, aminocarboxylic acids, 1, 3-diketones, hydroxycarboxylic acids, polyamines, amino alcohols, heterocyclic aromatic bases, aminophenols, Schiff's bases, tetrapyrroles, sulfur compounds, synthetic macrocyclic compounds, polymers and phosphonic acids.
  • useful chelating agents can comprise elhylenediamine tetraacetic acid (EDTA) , aminotriacetic acid, diethylene triaminepentaacetic acid, and a salt thereof, e.g., N, N-bis (carboxymethyl) glutamic acid, disodium EDTA, tetrasodium EDTA, tetrasodium salt of N, N-bis (carboxymethyl) glutamic acid (glutamic acid diacetic acid, GLDA) ; hydroxyl carboxylic acids, e.g., citric acid, tartaric acid, glucuronic acid, succinic acid, ethylenediamine disuccinic acid (EDDS) , and a salt thereof; hydroxyl aminocarboxylic acids, e.g., hydroxyethylethylenediamine triacetic acid (HEDTA) , dihydroxyethylglycine (DEG) , and a salt thereof; poly(ethylenediamine t
  • these agents are particularly useful for reducing the electrostatic bonding associated with substantial presence of water in the intermediate makeup and/or care composition according to the invention.
  • a sequestrant or of a complexing agent for instance disodium/tetrasodium EDTA, makes it possible to complex the free ions, and more specifically the cations of the type Ca 2+ (mineral fillers) especially present in the nacres and fillers. Consequently, when EDTA complexes these ions, the ionic strength of the water decreases.
  • this agent is chosen from aminocarboxylic acids, and is preferably EDTA or a derivative thereof.
  • a useful chelating agent is chosen from sodium citrate, disodium EDTA, tetrasodium EDTA, tetrasodium GLDA, trisodium EDDS, phytic acid, sodium phytate, potassium phytate, and mixtures thereof.
  • the chelating agent can be present in the composition from 0.001%to 5%by weight, preferably from 0.01%to 0.1%by weight, or preferably from 0.1%to 0.5%by weight, relative to the total weight of the composition according to the present invention.
  • composition according to the invention can comprise at least one polysaccharide, which is preferably of biotechnological origin.
  • these polysaccharides may, where appropriate, be chemically modified to promote its hydrophilic valency, as is the case for cellulose derivatives, in particular hydroxyalkylcelluloses (e.g.: hydroxyethylcellulose) .
  • polysaccharides that may be used according to the invention, mention may be made especially of:
  • algal extracts such as alginates, carrageenans and agar-agar, and mixtures thereof.
  • carrageenans examples include Satiagum and from the company Degussa; an alginate that may be mentioned is the sodium alginate sold under the name by the company ISP;
  • gums such as xanthan gum, gellan gum, guar gum and nonionic derivatives thereof (hydroxypropyl guar) , gum arabic, konjac gum or mannan gum, gum tragacanth, ghatti gum, karaya gum, locust bean gum, agar gum, scleroglucan gums and mixtures thereof; examples that may be mentioned include the xanthan gum sold under the name CG-T by the company CP Kelco, gellan gum sold under the name CG LA by the company CP Kelco, guar gum sold under the name Jaguar HP by the company Rhodia; mannan gum and konjac (1%glucomannan) sold by the company GfN;
  • xanthan gum such as xanthan gum, gellan gum, guar gum and nonionic derivatives thereof (hydroxypropyl guar) , gum arabic, konjac gum or mannan gum, gum tragacanth, ghatti gum, karaya gum,
  • starches which are preferably modified, such as those derived, for example, from cereals such as wheat, corn or rice, from legumes such as white lentil, from tubers such as potato or cassava, tapioca starches; dextrins, such as corn dextrins; Amidon de from the company Roquette; potato feculent modified with 2-chloroethylaminodipropionic acid neutralized with sodium hydroxide, sold under the name Structure by the company National Starch; native tapioca starch powder sold under the name Tapioca by the company National Starch;
  • dextrins such as dextrin extracted from corn under the name from the company National Starch;
  • celluloses and derivatives thereof in particular alkyl or hydroxyalkylcelluloses; mention may be made especially of methylcelluloses, hydroxyalkylcelluloses, ethylhydroxyethylcelluloses and carboxymethylcelluloses. Examples that may be mentioned include the hydroxyethylcellulose sold under the name Natrosol TM 250 HHR PC by the company Ashland, or under the name Cellosize TM QP 4400 H by the company Amerchol (Dow Chemical) , cetylhydroxyethylcelluloses sold under the names Polysurf and Natrosol Plus from Aqualon;
  • polyholosides comprising at least two saccharides, preferably of natural origin, and especially chosen from:
  • ribose arabinose, xylose or apiose, for example,
  • glucose, fucose, mannose or galactose for example
  • - deoxyoses such as rhamnose, digitoxose, cymarose or oleandrose,
  • - saccharide derivatives such as uronic acids, for instance mannuronic acid, guluronic acid, galacturonic acid or glycuronic acid, or itols, for instance mannitol or sorbitol.
  • polyholosides comprising fucose, galactose and galacturonic acid units, and for example a linear sequence of ⁇ -L-fucose, ⁇ -D-galactose and galacturonic acid, for instance the biosaccharide gum-1 sold under the trade name 1000 PP or 1.5P by the company Solabia,
  • anionic polysaccharides in particular of biotechnological origin, such as anionic polysaccharide bearing as repeating unit a tetrasaccharide composed of L-fucose, D-glucose and glucuronic acid, such as the product bearing the INCI name Biosaccharide Gum-4 sold under the reference Glycofilm 1.5P by the company Solabia,
  • polysaccharide of the present invention is chosen from:
  • - gums such as xanthan gum, or gellan gum
  • the polysaccharide such as According to an embodiment, can also serve as a gelling agent for the composition of the present invention.
  • the polysaccharide can be present in the composition in an amount ranging from 0.0001%to 5%by weight, preferably from 0.001%to 2%by weight, or from 0.005%to 1%by weight of the polysaccharides, relative to the total weight of the composition.
  • composition according to the invention may advantageously comprise one or more additional active ingredients, in particular cosmetic, dermatological or pharmaceutical.
  • an additional active ingredient is an active ingredient other than polydatin or resveratrol present in the composition and the other active agents specifically defined above.
  • such additional active ingredient, cosmetic, dermatological or pharmaceutical may be intended to exert a cosmetic, care or hygiene effect on keratin materials such as skin, including face, hair, eyelashes, scalp and/or leather hairy, and preferentially on the skin.
  • composition according to the invention may further comprise an active ingredient having an anti-aging activity, or a hydration activity.
  • These additional active ingredients are generally present in the composition in a content ranging from 0.0001%to 20%by weight and preferably from 0.01%to 10%by weight relative to the total weight of said composition.
  • compositions of the present invention are provided for application to skin.
  • the compositions of the present invention can comprise various ingredients conventionally useful in compositions for conditioning skin, such as, humectants, fatty substances, antidandruff agents, anti-seborrhoea agents, agents for preventing loss and/or for promoting regrowth, vitamins and provitamins including panthenol, sunscreens, sequestrants, plasticizers, acidifying agents, opacifiers, pearlescent or nacreous agents, antioxidants, hydroxyacids, fragrances and preserving agents.
  • ingredients conventionally useful in compositions for conditioning skin such as, humectants, fatty substances, antidandruff agents, anti-seborrhoea agents, agents for preventing loss and/or for promoting regrowth, vitamins and provitamins including panthenol, sunscreens, sequestrants, plasticizers, acidifying agents, opacifiers, pearlescent or nacreous agents, antioxidants, hydroxya
  • additives may be selected variously by the person skilled in the art in order to prepare a composition which has the desired properties, for example, consistency or texture.
  • the additives, if used, and the amounts thereof are particularly determined according to the specific products/applications thereof, e.g., leave-on conditioner, rinse-off conditioner, skincare conditioner and the like.
  • additives may be present in the composition in an amount from 0.01%to 50%relative to the total weight of the composition, including all ranges and subranges therebetween.
  • composition according to the present invention can be generally prepared according to the general knowledge of a person skilled in the art. Nevertheless, it is to be understood that a person skilled in the art can choose the method of preparation, on the basis of his/her general knowledge, taking into account the nature of the constituents used, for example, their solubility in the vehicle, and the application envisaged for the compositions or the kit.
  • composition according to the present invention can be used to formulate products useful for cosmetic use, e.g., for caring for keratin materials.
  • composition according to the present invention is preferably useful to formulate skincare products. Also, according to the detailed discussions above, it is to be understood that the composition according to the present invention may be free of silicone oil.
  • the present invention thus provides use of the composition according to the present invention for enhancing the performance of a cosmetic and/or therapeutic product while avoiding or reducing the irritation suffered by skin.
  • compositions/formulas described below were expressed in %by weight, relative to the total weight of each composition/formula.
  • AMMONIUM ACRYLOYLDIMETHYLTAURATE/STEARETH-25 METHACRYLATE CROSSPOLYMER ARISTOFLEX HMS, available from CLARIANT;
  • PEG-7GLYCERYL COCOATE CETIOL HE, available from BASF;
  • compositions were prepared according to Example 1 and Comparative Examples 1-4 as in Table 1 below:
  • compositions were prepared according to known manufacturing method of field. Briefly, the procedure of preparing the compositions comprised the steps of:
  • compositions on the cell viability were determined, comprising the steps of: applying effective amount the compositions on reconstructed skin model, standing, and then making statistic of the viable cell amount.
  • the more viability meant the more comfort level.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

Une composition aqueuse pour améliorer un tensioactif comprend les composants suivants : A) au moins un copolymère AMPS hydrophobe ; B) au moins un tensioactif irritant classiquement, ayant une viabilité cellulaire EpiSkin égale ou inférieure à 90 %, de préférence égale ou inférieure à 85 % ; et C) un solvant/milieu.
PCT/CN2021/078213 2021-02-26 2021-02-26 Composition pour améliorer un tensioactif WO2022178848A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202180094694.8A CN116940321A (zh) 2021-02-26 2021-02-26 用于改进表面活性剂的组合物
PCT/CN2021/078213 WO2022178848A1 (fr) 2021-02-26 2021-02-26 Composition pour améliorer un tensioactif
FR2102884A FR3120195B1 (fr) 2021-02-26 2021-03-23 Composition pour améliorer le tensioactif

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2021/078213 WO2022178848A1 (fr) 2021-02-26 2021-02-26 Composition pour améliorer un tensioactif

Publications (1)

Publication Number Publication Date
WO2022178848A1 true WO2022178848A1 (fr) 2022-09-01

Family

ID=83047658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/078213 WO2022178848A1 (fr) 2021-02-26 2021-02-26 Composition pour améliorer un tensioactif

Country Status (3)

Country Link
CN (1) CN116940321A (fr)
FR (1) FR3120195B1 (fr)
WO (1) WO2022178848A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013107001A1 (fr) * 2012-01-17 2013-07-25 L'oreal Composition à changement de couleur contenant un ou plusieurs filtres uv
US20160095804A1 (en) * 2014-10-01 2016-04-07 L'oreal Sulfate-free cleansing composition with thickener
US20180311139A1 (en) * 2017-04-28 2018-11-01 L'oreal Hair-treatment compositions comprising a polyurethane latex polymer and cationic compound
US20190240123A1 (en) * 2016-10-28 2019-08-08 L'oreal Composition comprising at least two fatty acid esters of (poly)glycerol, and use thereof in cosmetics
US20210000731A1 (en) * 2018-03-05 2021-01-07 Dsm Ip Assets B.V. Topical composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1567947A (en) 1976-07-02 1980-05-21 Unilever Ltd Esters of quaternised amino-alcohols for treating fabrics
US4578267A (en) * 1981-09-15 1986-03-25 Morton Thiokol, Inc. Skin conditioning polymer containing alkoxylated nitrogen salts of sulfonic acid
DE3623215A1 (de) 1986-07-10 1988-01-21 Henkel Kgaa Neue quartaere ammoniumverbindungen und deren verwendung
US7879316B2 (en) 2002-06-12 2011-02-01 L'oreal Cosmetic composition containing a polyorganosiloxane polymer
US7455848B2 (en) * 2002-12-18 2008-11-25 Nalco Company Skin care composition containing an anionic polymer
EP1846007A1 (fr) * 2005-01-31 2007-10-24 Robert D. Kross Polymere dermoprotecteur destine a une utilisation dans les compositions de soins des trayons
FR3060379B1 (fr) * 2016-12-19 2019-07-05 L'oreal Composition comprenant un polymere d'amps, de la montmorillonite, de la silice et du kaolin
WO2019086275A1 (fr) * 2017-11-03 2019-05-09 Unilever Plc Composition nettoyante pour la peau et méthode d'utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013107001A1 (fr) * 2012-01-17 2013-07-25 L'oreal Composition à changement de couleur contenant un ou plusieurs filtres uv
US20160095804A1 (en) * 2014-10-01 2016-04-07 L'oreal Sulfate-free cleansing composition with thickener
US20190240123A1 (en) * 2016-10-28 2019-08-08 L'oreal Composition comprising at least two fatty acid esters of (poly)glycerol, and use thereof in cosmetics
US20180311139A1 (en) * 2017-04-28 2018-11-01 L'oreal Hair-treatment compositions comprising a polyurethane latex polymer and cationic compound
US20210000731A1 (en) * 2018-03-05 2021-01-07 Dsm Ip Assets B.V. Topical composition

Also Published As

Publication number Publication date
CN116940321A (zh) 2023-10-24
FR3120195A1 (fr) 2022-09-02
FR3120195B1 (fr) 2024-03-01

Similar Documents

Publication Publication Date Title
US11376207B2 (en) Hair care compositions
EP2941237B1 (fr) Composition cosmétique
US8057786B2 (en) Cosmetic and dermatological compositions in particular for the treatment of keratin containing substrates
RU2454992C2 (ru) Композиции для ухода за волосами
EP2039751B1 (fr) Composition de nettoyage
WO2009148825A2 (fr) Compositions d'hydratation continue
EP3558248A1 (fr) Composition de nettoyage
US20220313571A1 (en) Combination of modified starch/c13-c15 fatty acid/clay
EP1148863B2 (fr) Compositions cosmetiques detergentes et utilisation
EP2039340B2 (fr) Composition de nettoyage de la peau
KR20240060596A (ko) 당지질 및 온화한 계면활성제를 포함하는 구강 케어 조성물
DE102013225753A1 (de) Kosmetisches Mittel
DE102009029110A1 (de) Antimikrobielle Formulierung
WO2022178848A1 (fr) Composition pour améliorer un tensioactif
WO2022178847A1 (fr) Composition pour le soin de matières kératiniques
WO2016066812A1 (fr) Savon liquide transparent
US20230390168A1 (en) Composition for conditioning keratin materials
WO2022178849A1 (fr) Composition de tensioactif à irritation réduite
KR20210154093A (ko) 라멜라 구조를 갖는 컨디셔닝 샴푸 조성물
WO2022041214A1 (fr) Composition pour le nettoyage de fibres de kératine et son utilisation
WO2021077320A1 (fr) Composition pour le soin de la peau
WO2023141803A1 (fr) Composition appropriée du fait de sa haute teneur en huile
JP7246362B2 (ja) 毛髪又は皮膚用洗浄剤組成物
CN116419741A (zh) 用于调理角蛋白材料的组合物
CN116367820A (zh) 用于调理角蛋白材料的组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21927284

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202180094694.8

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21927284

Country of ref document: EP

Kind code of ref document: A1